<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36639403</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Symptoms timeline and outcomes in amyotrophic lateral sclerosis using artificial intelligence.</ArticleTitle><Pagination><StartPage>702</StartPage><MedlinePgn>702</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">702</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-27863-2</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal, neurodegenerative motor neuron disease. Although an early diagnosis is crucial to provide adequate care and improve survival, patients with ALS experience a significant diagnostic delay. This study aimed to use real-world data to describe the clinical profile and timing between symptom onset, diagnosis, and relevant outcomes in ALS. Retrospective and multicenter study in 5 representative hospitals and Primary Care services in the SESCAM Healthcare Network (Castilla-La Mancha, Spain). Using Natural Language Processing (NLP), the clinical information in electronic health records of all patients with ALS was extracted between January 2014 and December 2018. From a source population of all individuals attended in the participating hospitals, 250 ALS patients were identified (61.6% male, mean age 64.7&#xa0;years). Of these, 64% had spinal and 36% bulbar ALS. For most defining symptoms, including dyspnea, dysarthria, dysphagia and fasciculations, the overall diagnostic delay from symptom onset was 11 (6-18) months. Prior to diagnosis, only 38.8% of patients had visited the neurologist. In a median post-diagnosis follow-up of 25&#xa0;months, 52% underwent gastrostomy, 64% non-invasive ventilation, 16.4% tracheostomy, and 87.6% riluzole treatment; these were more commonly reported (all Ps&#x2009;&lt;&#x2009;0.05) and showed greater probability of occurrence (all Ps&#x2009;&lt;&#x2009;0.03) in bulbar ALS. Our results highlight the diagnostic delay in ALS and revealed differences in the clinical characteristics and occurrence of major disease-specific events across ALS subtypes. NLP holds great promise for its application in the wider context of rare neurological diseases.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Segura</LastName><ForeName>Tom&#xe1;s</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University Hospital of Albacete, Albacete, Spain. tseguram@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medrano</LastName><ForeName>Ignacio H</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Savana Research, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collazo</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Savana Research, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mat&#xe9;</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Savana Research, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sguera</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Savana Research, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UC3M-Santander Big Data Institute, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Rio-Bermudez</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Savana Research, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casero</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Savana Research, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salcedo</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Savana Research, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Garc&#xed;a</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Hospital of Albacete, Albacete, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcahut-Rodr&#xed;guez</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Hospital of Albacete, Albacete, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Savana Research Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Taberna</LastName><ForeName>Miren</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Savana Research, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="N">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Aquino</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casadevall</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donaire</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marin-Corral</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menke</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polo</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>23</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36639403</ArticleId><ArticleId IdType="pmc">PMC9839769</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-27863-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-27863-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talbot K. Motor neuron disease. Bare Essentials. 2009;9:303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">19762894</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001;344:1688&#x2013;1700. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, et al. Prognostic factors in ALS: A critical review. Amyotroph. Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Charcot, J. &amp; Joffroy, A. Deux Cas d Atrophie Musculaire Progressive Avec Lesions de La substance Grise et des Faisceaux Antero-Lateraux de la Moelle Epiniere.</Citation></Reference><Reference><Citation>Brooks BR. Earlier is better: The benefits of early diagnosis. Neurology. 1999;53:S53&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10560640</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: An update of recent literature. Curr. Opin. Neurol. 2019;32:771&#x2013;776. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335&#x2013;1342. doi: 10.1001/jamaoncol.2017.0589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2017.0589</ArticleId><ArticleId IdType="pmc">PMC5824320</ArticleId><ArticleId IdType="pubmed">28448665</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomoll&#xf3;n F, et al. Clinical characteristics and prognostic factors for Crohn&#x2019;s disease relapses using natural language processing and machine learning: A pilot study. Eur. J. Gastroenterol. Hepatol. 2020;34:389&#x2013;397. doi: 10.1097/MEG.0000000000002317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000002317</ArticleId><ArticleId IdType="pmc">PMC8876385</ArticleId><ArticleId IdType="pubmed">34882644</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio-Bermudez CM, et al. Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy. J. Pharm. Policy Pract. 2020;13:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7650184</ArticleId><ArticleId IdType="pubmed">33292570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Juanatey C, et al. Assessment of medical management in Coronary Type 2 Diabetic patients with previous percutaneous coronary intervention in Spain: A retrospective analysis of electronic health records using Natural Language Processing. PLoS ONE. 2022;17:e0263277. doi: 10.1371/journal.pone.0263277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0263277</ArticleId><ArticleId IdType="pmc">PMC8830700</ArticleId><ArticleId IdType="pubmed">35143527</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikhalishahi S, Miotto R, Dudley JT, Lavelli A, Rinaldi F, Osmani V. Natural language processing of clinical notes on chronic diseases: Systematic review. JMIR Med. Inform. 2019;7:e12239. doi: 10.2196/12239.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/12239</ArticleId><ArticleId IdType="pmc">PMC6528438</ArticleId><ArticleId IdType="pubmed">31066697</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein BA, Navar AM, Pencina MJ, Ioannidis JP. Opportunities and challenges in developing risk prediction models with electronic health records data: A systematic review. J. Am. Med. Inform. Assoc. 2017;24:198&#x2013;208. doi: 10.1093/jamia/ocw042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocw042</ArticleId><ArticleId IdType="pmc">PMC5201180</ArticleId><ArticleId IdType="pubmed">27189013</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Thompson WK, Herr TM, Zeng Z, Berendsen MA, Jonnalagadda SR, Carson MB, Starren J. Natural language processing for EHR-based pharmacovigilance: A structured review. Drug Saf. 2017;40:1075&#x2013;1089. doi: 10.1007/s40264-017-0558-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-017-0558-6</ArticleId><ArticleId IdType="pubmed">28643174</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo JL, Almonacid C, Gonz&#xe1;lez Y, Del Rio-Berm&#xfa;dez C, Ancochea J, C&#xe1;rdenas R, Soriano JB. The impact of COVID-19 on patients with asthma. Eur. Respir. J. 2020;43:425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7651839</ArticleId><ArticleId IdType="pubmed">33154029</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo JL, Ancochea J, Soriano JB. Clinical characteristics and prognostic factors for intensive care unit admission of patients with COVID-19: Retrospective study using machine learning and natural language processing. J. Med. Internet Res. 2020;22:e21801. doi: 10.2196/21801.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/21801</ArticleId><ArticleId IdType="pmc">PMC7595750</ArticleId><ArticleId IdType="pubmed">33090964</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez Medrano ITG, et al. Savana: Re-using electronic health records with artificial intelligence. Int. J. Interact. Multimed. Artif. Intell. 2017;4:8&#x2013;12.</Citation></Reference><Reference><Citation>Ancochea J, Izquierdo JL, Medrano IH, Porras A, Serrano M, Lumbreras S, Del Rio-Bermudez C, Marchesseau S, Salcedo I, Zubizarreta I, Gonz&#xe1;lez Y, Soriano JB. Evidence of gender differences in the diagnosis and management of COVID-19 patients: An analysis of electronic health records using natural language processing and machine learning. J. Women Health. 2020;30:393&#x2013;404. doi: 10.1089/jwh.2020.8721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jwh.2020.8721</ArticleId><ArticleId IdType="pubmed">33416429</ArticleId></ArticleIdList></Reference><Reference><Citation>Canales L, Menke S, Marchesseau S, D'Agostino A, Del Rio-Bermudez C, Taberna M, Tello J. Assessing the performance of clinical natural language processing systems: Development of an evaluation methodology. JMIR Med. Inform. 2021;9:e20492. doi: 10.2196/20492.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/20492</ArticleId><ArticleId IdType="pmc">PMC8367121</ArticleId><ArticleId IdType="pubmed">34297002</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J. Neurol. Sci. 1994;124:96&#x2013;107. doi: 10.1016/0022-510X(94)90191-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90191-0</ArticleId><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa-Anke LT, et al. Savana: A global information extraction and terminology expansion framework in the medical domain Procesamiento del Lenguaje. Natural. 2016;57:23&#x2013;30.</Citation></Reference><Reference><Citation>Longinetti E, Regod&#xf3;n Wallin A, Samuelsson K, Press R, Zachau A, Ronnevi LO, Kierkegaard M, Andersen PM, Hillert J, Fang F, et al. The Swedish motor neuron disease quality registry. Amyotroph. Lateral Scler. Frontotemporal Degener. 2018;19:528&#x2013;537. doi: 10.1080/21678421.2018.1497065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1497065</ArticleId><ArticleId IdType="pubmed">30296856</ArticleId></ArticleIdList></Reference><Reference><Citation>Palese F, Sartori A, Verriello L, Ros S, Passadore P, Manganotti P, Barbone F, Pisa FE. Epidemiology of amyotrophic lateral sclerosis in Friuli-Venezia Giulia, North-Eastern Italy, 2002&#x2013;2014: A retrospective population-based study. Amyotroph. Lateral Scler. Frontotemporal Degener. 2019;20:90&#x2013;99. doi: 10.1080/21678421.2018.1511732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1511732</ArticleId><ArticleId IdType="pubmed">30430867</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Rodr&#xed;guez E, Azagra R, G&#xf3;mez-Batiste X, Povedano M. Amyotrophic lateral sclerosis (ALS) from the perspective of primary care. Epidemiology and clinical-care characteristics. Aten Primaria. 2021;53:102158. doi: 10.1016/j.aprim.2021.102158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aprim.2021.102158</ArticleId><ArticleId IdType="pmc">PMC8435918</ArticleId><ArticleId IdType="pubmed">34509895</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun KY, Park J, Oh K-W, Kim EM, Bae JS, Kim I, Kim SH. Epidemiology of ALS in Korea using nationwide big data. J. Neurol. Neurosurg. Psychiatry. 2019;90:395&#x2013;403. doi: 10.1136/jnnp-2018-318974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318974</ArticleId><ArticleId IdType="pmc">PMC6581156</ArticleId><ArticleId IdType="pubmed">30409890</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjaminsen E, Alstadhaug KB, Gulsvik M, Baloch FK, Odeh F. Amyotrophic lateral sclerosis in Nordland county, Norway, 2000&#x2013;2015: Prevalence, incidence, and clinical features. Amyotroph. Lateral Scler. Frontotemporal Degener. 2018;19:522&#x2013;527. doi: 10.1080/21678421.2018.1513534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1513534</ArticleId><ArticleId IdType="pubmed">30265157</ArticleId></ArticleIdList></Reference><Reference><Citation>Swingler RJ, Fraser H, Warlow CP. Motor neuron disease and polio in Scotland. J. Neurol. Neurosurg. Psychiatry. 1992;55:1116&#x2013;1120. doi: 10.1136/jnnp.55.12.1116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.55.12.1116</ArticleId><ArticleId IdType="pmc">PMC1015322</ArticleId><ArticleId IdType="pubmed">1479388</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S, Kollewe K, Ilsemann J, M&#xfc;ller-Heine A, Dengler R, Krampfl K, Petri S. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur. J. Neurol. 2013;20:647&#x2013;654. doi: 10.1111/ene.12015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12015</ArticleId><ArticleId IdType="pubmed">23094606</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekmann K, Kuzma-Kozakiewicz M, Piotrkiewicz M, Gromicho M, Grosskreutz J, Andersen PM, de Carvalho M, Uysal H, Osmanovic A, Schreiber-Katz O, et al. Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. J. Neurol. 2020;267:2130&#x2013;2141. doi: 10.1007/s00415-020-09799-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09799-z</ArticleId><ArticleId IdType="pubmed">32266542</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Molina M, Argente-Escrig H, Polo MF, Herv&#xe1;s D, Frasquet M, Cort&#xe9;s V, Sevilla T, V&#xe1;zquez-Costa JF. Early referral to an ALS center reduces several months the diagnostic delay: A multicenter-based study. Front. Neurol. 2020;11:604922. doi: 10.3389/fneur.2020.604922.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.604922</ArticleId><ArticleId IdType="pmc">PMC7775542</ArticleId><ArticleId IdType="pubmed">33391167</ArticleId></ArticleIdList></Reference><Reference><Citation>Falc&#xe3;o de Campos C, Gromicho M, Uysal H, Grosskreutz J, Kuzma-Kozakiewicz M, Oliveira Santos M, Pinto S, Petri S, Swash M, de Carvalho M. Delayed diagnosis and diagnostic pathway of ALS patients in Portugal: Where can we improve? Front Neurol. 2021;12:761355. doi: 10.3389/fneur.2021.761355.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.761355</ArticleId><ArticleId IdType="pmc">PMC8596501</ArticleId><ArticleId IdType="pubmed">34803894</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez-Costa JF, Mart&#xed;nez-Molina M, Fern&#xe1;ndez-Polo M, Forn&#xe9;s-Ferrer V, Frasquet-Carrera M, Sevilla-Mantec&#xf3;n T. Analysis of the diagnostic pathway and delay in patients with amyotrophic lateral sclerosis in the Valencian Community. Neurologia. 2021;36:504&#x2013;513. doi: 10.1016/j.nrl.2018.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nrl.2018.03.026</ArticleId><ArticleId IdType="pubmed">34537164</ArticleId></ArticleIdList></Reference><Reference><Citation>Kano O, Iwamoto K, Ito H, Kawase Y, Cridebring D, Ikeda K, Iwasaki Y. Limb-onset amyotrophic lateral sclerosis patients visiting orthopedist show a longer time-to-diagnosis since symptom onset. BMC Neurol. 2013;13:19. doi: 10.1186/1471-2377-13-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-13-19</ArticleId><ArticleId IdType="pmc">PMC3576252</ArticleId><ArticleId IdType="pubmed">23394455</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage N. Calculating disease. Nature. 2017;550:S115&#x2013;S117. doi: 10.1038/550S115a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/550S115a</ArticleId><ArticleId IdType="pubmed">29045372</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittel S, Maier A, Kettemann D, Walter B, Koch B, Krause K, Norden J, M&#xfc;nch C, Meyer T. Non-invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany. Eur. J. Neurol. 2021;28:1160&#x2013;1171. doi: 10.1111/ene.14647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14647</ArticleId><ArticleId IdType="pubmed">33210770</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, Scialo C, Sorar&#xf9; G, Trojsi F, Conte A, et al. Factors predicting survival in ALS: A multicenter Italian study. J. Neurol. 2017;264:54&#x2013;63. doi: 10.1007/s00415-016-8313-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8313-y</ArticleId><ArticleId IdType="pubmed">27778156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceriana P, Surbone S, Segagni D, Schreiber A, Carlucci A. Decision-making for tracheostomy in amyotrophic lateral sclerosis (ALS): a retrospective study. Amyotroph. Lateral Scler. Frontotemporal Degener. 2017;18:492&#x2013;497. doi: 10.1080/21678421.2017.1317812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1317812</ArticleId><ArticleId IdType="pubmed">28457142</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Ghiglione P, Mazzini L, Mutani R, Mora G. Tracheostomy in amyotrophic lateral sclerosis: A 10-year population-based study in Italy. J. Neurol. Neurosurg. Psychiatry. 2010;81:1141&#x2013;1143. doi: 10.1136/jnnp.2009.175984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.175984</ArticleId><ArticleId IdType="pubmed">20660920</ArticleId></ArticleIdList></Reference><Reference><Citation>Melo J, Homma A, Iturriaga E, Frierson L, Amato A, Anzueto A, Jackson C. Pulmonary evaluation and prevalence of non-invasive ventilation in patients with amyotrophic lateral sclerosis: A multicenter survey and proposal of a pulmonary protocol. J. Neurol. Sci. 1999;169:114&#x2013;117. doi: 10.1016/S0022-510X(99)00228-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00228-2</ArticleId><ArticleId IdType="pubmed">10540018</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoesmith CL, Findlater K, Rowe A, Strong MJ. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J. Neurol. Neurosurg. Psychiatry. 2007;78:629&#x2013;631. doi: 10.1136/jnnp.2006.103564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.103564</ArticleId><ArticleId IdType="pmc">PMC2077959</ArticleId><ArticleId IdType="pubmed">17088331</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2002;2002:CD001447.</Citation><ArticleIdList><ArticleId IdType="pubmed">12076411</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Jackson CE, Heiman-Patterson TD, Bettica P, Brooks BR, Pioro EP. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2020;21:509&#x2013;518. doi: 10.1080/21678421.2020.1771734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>Grollemund V, Pradat P-F, Querin G, Delbot F, Le Chat G, Pradat-Peyre J-F, Bede P. Machine learning in amyotrophic lateral sclerosis: Achievements, pitfalls, and future directions. Front. Neurosci. 2019;13:135&#x2013;135. doi: 10.3389/fnins.2019.00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00135</ArticleId><ArticleId IdType="pmc">PMC6403867</ArticleId><ArticleId IdType="pubmed">30872992</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso S, Meneton P, Aim&#xe9; X, Meininger V, Grabli D, Guezennec G, Charlet J. Use of a modular ontology and a semantic annotation tool to describe the care pathway of patients with amyotrophic lateral sclerosis in a coordination network. PLoS ONE. 2021;16:e0244604. doi: 10.1371/journal.pone.0244604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244604</ArticleId><ArticleId IdType="pmc">PMC7787442</ArticleId><ArticleId IdType="pubmed">33406098</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdoch TB, Detsky AS. The inevitable application of big data to health care. JAMA. 2013;309:1351&#x2013;1352. doi: 10.1001/jama.2013.393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.393</ArticleId><ArticleId IdType="pubmed">23549579</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio-Bermudez C, Medrano IH, Yebes L, Poveda JL. Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy. J. Pharm. Policy Pract. 2020;13:75. doi: 10.1186/s40545-020-00276-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40545-020-00276-6</ArticleId><ArticleId IdType="pmc">PMC7650184</ArticleId><ArticleId IdType="pubmed">33292570</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster C, Hardiman O, Bede P. Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurol. 2017;17:73. doi: 10.1186/s12883-017-0854-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-017-0854-x</ArticleId><ArticleId IdType="pmc">PMC5393027</ArticleId><ArticleId IdType="pubmed">28412941</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Q, Cai T, Hong C, Du M, Johnson BE, Lanuti M, Cai T, Christiani DC. Performance of a machine learning algorithm using electronic health record data to identify and estimate survival in a longitudinal cohort of patients with lung cancer. JAMA Netw. Open. 2021;4:e2114723&#x2013;e2114723. doi: 10.1001/jamanetworkopen.2021.14723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.14723</ArticleId><ArticleId IdType="pmc">PMC8264641</ArticleId><ArticleId IdType="pubmed">34232304</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>